Passa al contenuto
Merck
Tutte le immagini(2)

Documenti

S3378

Sigma-Aldrich

Spironolactone

97.0-103.0% (HPLC), powder, aldosterone receptor antagonist

Sinonimo/i:

4-Pregnen-21-oic acid-17α-ol-3-one-7α-thiol γ-lactone 7-acetate, 7α-(Acetylthio)-17α-hydroxy-3-oxopregn-4-ene-21-carboxylic acid γ-lactone

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
Tutte le immagini(2)

About This Item

Formula empirica (notazione di Hill):
C24H32O4S
Numero CAS:
52-01-7
Peso molecolare:
416.57
Numero CE:
200-133-6
Numero MDL:
MFCD00082250
Codice UNSPSC:
51111800
ID PubChem:
24277736
NACRES:
NA.77

product name

Spironolactone, 97.0-103.0%

Saggio

97.0-103.0%

Punto di fusione

207-208 °C (lit.)

Solubilità

chloroform: complete 50 mg/ml, clear, faintly yellow

Stringa SMILE

CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CC[C@@]45CCC(=O)O5)[C@H]13

InChI

1S/C24H32O4S/c1-14(25)29-19-13-15-12-16(26)4-8-22(15,2)17-5-9-23(3)18(21(17)19)6-10-24(23)11-7-20(27)28-24/h12,17-19,21H,4-11,13H2,1-3H3/t17-,18-,19+,21+,22-,23-,24+/m0/s1
LXMSZDCAJNLERA-ZHYRCANASA-N

Informazioni sul gene

human ... HSD17B1(3292) , NR3C2(4306)
rat ... Ar(24208)

Cerchi prodotti simili? Visita Guida al confronto tra prodotti

Applicazioni

Spironolactone was added to rat diet to study the effect of long-term spironolactone use on renal function.

Azioni biochim/fisiol

Spironolactone reduces aldosterone-induced potassium/magnesium loss and myocardial fibrosis. It reduces hypertension, improves the endothelial function and reduces the overall morbidity and mortality in patients with chronic heart failure. Spironolactone improves nitric oxide bioactivity and vascular endothelial vasodilator dysfunction.
Spironolactone is a competitive aldosterone receptor antagonist. Used as potassium sparing diuretic.

Caratteristiche e vantaggi

This compound is featured on the Nuclear Receptors (Steroids) page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

Nota sulla preparazione

Spironolactone yields clear, faint yellow solution in chloroform at 50 mg/ml.

Pittogrammi

Health hazard
GHS08

Avvertenze

Danger

Indicazioni di pericolo

H351,H360FD,H373

Classi di pericolo

Carc. 2 - Repr. 1B - STOT RE 2

Codice della classe di stoccaggio

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

Classe di pericolosità dell'acqua (WGK)

WGK 3

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable

Dispositivi di protezione individuale

Eyeshields, Gloves, type P2 (EN 143) respirator cartridges

Certificati d'analisi (COA)

Cerca il Certificati d'analisi (COA) digitando il numero di lotto/batch corrispondente. I numeri di lotto o di batch sono stampati sull'etichetta dei prodotti dopo la parola ‘Lotto’ o ‘Batch’.

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

I clienti hanno visto anche

Slide 1 of 6

1 of 6

Eplerenone European Pharmacopoeia (EP) Reference Standard, European Pharmacopoeia (EP) Reference Standard

Y0001704

Eplerenone

Canrenone European Pharmacopoeia (EP) Reference Standard

C0410000

Canrenone

Canrenoic acid potassium salt powder

Sigma-Aldrich

C7287

Canrenoic acid potassium salt

Pravastatin, Sodium Salt A water-soluble, competitive 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor that potently blocks in vivo cholesterol synthesis (Ki = ~1 nM).

Sigma-Aldrich

524403

Pravastatin, Sodium Salt

vibrant-m

D0600000

Deslanoside

5-(N,N-Dimethyl)amiloride hydrochloride

Sigma-Aldrich

A4562

5-(N,N-Dimethyl)amiloride hydrochloride

Femke Waanders et al.
American journal of physiology. Renal physiology, 296(5), F1072-F1079 (2009-02-27)
Chronic transplant dysfunction (CTD) is the leading cause of long-term renal allograft loss and is characterized by specific histological lesions including transplant vasculopathy, interstitial fibrosis, and focal glomerulosclerosis. Increasing evidence indicates that aldosterone is a direct mediator of renal damage
Donna A Volpe et al.
The AAPS journal, 16(1), 172-180 (2013-12-18)
Drug interactions due to efflux transporters may result in one drug increasing or decreasing the systemic exposure of a second drug. The potential for in vivo drug interactions is estimated through in vitro cell assays. Variability in in vitro parameter
P Moghetti et al.
The Journal of clinical endocrinology and metabolism, 84(4), 1250-1254 (1999-04-13)
GnRH agonists (GnRHa) have recently been proposed for the treatment of hirsutism in women with the polycystic ovary syndrome (PCOS). As most of these subjects have increased androgen secretion from both ovaries and adrenal glands, the association of GnRHa with
A Sato et al.
Hypertension research : official journal of the Japanese Society of Hypertension, 22(1), 17-22 (1999-04-30)
There is increasing evidence for important cardiovascular effects of aldosterone via classical mineralocorticoid receptors in the heart. Administration of aldosterone with excess salt produces both cardiac hypertrophy and interstitial cardiac fibrosis in rats, and concomitant administration of potassium canrenoate at
B Pitt et al.
The New England journal of medicine, 341(10), 709-717 (1999-09-02)
Aldosterone is important in the pathophysiology of heart failure. In a doubleblind study, we enrolled 1663 patients who had severe heart failure and a left ventricular ejection fraction of no more than 35 percent and who were being treated with
Visualizza tutti i documenti correlati

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.